1. Introduction {#s0005}
===============

Methadone maintenance is an established treatment for the management of opioid dependence, and is significantly associated with reductions in illicit opioid use ([@bb0070], [@bb0100]), injection drug use and equipment-sharing ([@bb0070]), and HIV transmission ([@bb0005]). A Cochrane review found a nonsignificant trend of reductions in mortality associated with methadone maintenance treatment (MMT) ([@bb0100]). Moreover, [@bb0030] reported a seven-fold increased risk of overdose death while not in MMT in a cohort study of heroin users. These findings are especially pertinent given the recent increase in opioid use-related overdose deaths in North American jurisdictions ([@bb0025], [@bb0150]). In Vancouver, Canada, the drug use-related overdose death rate more than tripled between 2012 and 2016 ([@bb0025]) and has overwhelmed first responders ([@bb0040]).

Homeless people are particularly vulnerable to substance use-related harms, as inadequate/unstable housing can be a significant structural determinant of risk behaviors ([@bb0010]). Homelessness is independently associated with needle use and sharing ([@bb0010]) as well as nonfatal drug overdose ([@bb0050]). A study from Boston, Massachusetts, reported opioid overdose as a major cause of death among homeless adults ([@bb0020]). MMT thus has strong potential as a treatment and prevention tool among homeless people experiencing opioid dependence.

Poor adherence to MMT increases the risk of overdose through changes to the central nervous system ([@bb0180]). However, MMT adherence research is limited ([@bb0145]). Existing studies have generally used shorter observation periods ranging from a week to over 2 years ([@bb0075], [@bb0130], [@bb0145], [@bb0155], [@bb0190]), and, in one case, eight years ([@bb0195]). Longer observation periods may enable more stable estimates of adherence. Moreover, to our knowledge, no studies have reported adherence to MMT among homeless populations.

The current study addresses the aforementioned gaps by being the first to investigate methadone adherence in a well-defined sample of people experiencing both homelessness and mental illness over a period of 15 years using comprehensive pharmacy dispensing data. Our objectives were to identify the prevalence of MMT within the sample, investigate adherence levels over a multi-year period, report characteristics that may differentiate methadone recipients from others in the sample, and identify potential correlates of adherence. Such information is needed to inform MMT programs serving homeless populations and future research, as the level of MMT adherence in this population remains unknown. Cost-effectiveness studies are also important in this area, but at this point, there are very few studies with descriptive details involving MMT among marginalized samples, so an additional goal of the present study was to contribute descriptive information related to cost of MMT, to inform future research.

2. Material and methods {#s0010}
=======================

2.1. Data sources and participants {#s0015}
----------------------------------

Analysis was based on administrative and self-reported data from participants in the Vancouver At Home (VAH) study. VAH is comprised of two randomized trials of Housing First interventions for homeless adults experiencing mental illness in Vancouver, British Columbia (BC) ([@bb0165]). Participants were recruited between October 2009 and June 2011, and met the following inclusion criteria: a minimum age of 19, absolute homelessness or unstable housing, and mental illness. Absolute "homelessness was defined as having no fixed place to sleep or live for more than 7 nights and little likelihood of obtaining accommodation in the coming month" ([@bb0165], p. 3). Unstable "housing was defined as currently residing in marginal accommodation, such as a SRO hotel, and having two or more episodes of \[absolute\] homelessness (as defined above) during the past 12 months" ([@bb0165], p. 3). Comprehensive diagnostic and prescription data were obtained from BC\'s Medical Services Plan (MSP) ([@bb0055]) and BC PharmaNet ([@bb0065]). MSP is the universal health insurance plan in British Columbia ([@bb0055]). PharmaNet is an administrative database containing information related to prescription drug dispensation from all pharmacies in BC ([@bb0065]).

Separate consent was required for 1) participation in VAH and 2) access to administrative records, including MSP and PharmaNet data. The Institutional ethics review board of Simon Fraser University approved the current study. Further details unrelated to the present study have been described separately ([@bb0140], [@bb0165]).

Baseline data from VAH and descriptive longitudinal data from MSP and PharmaNet were analyzed. Retrospective PharmaNet data were available from January 1, 1996 to VAH baseline (≈ 15 years). All participants dispensed methadone between January 1, 1996 and baseline were included in analyses. A diagnosis of "drug dependence" occurring at any point during the 15 years preceding VAH baseline was identified from MSP billing data. Drug dependence can be entered into MSP by any community-based health care practitioner qualified to diagnose, using the International Classification of Diseases-9 code of 304.

2.2. MMT adherence and descriptive variables {#s0020}
--------------------------------------------

Methadone treatment in BC is prescribed by MMT-authorized physicians ([@bb0035]). Daily oral methadone is administered at pharmacies, and consumption is observed by pharmacists, unless take-home doses are prescribed ([@bb0035]). MMT is provided at no cost via a provincially sponsored plan (known as BC PharmaCare) to low-income patients ([@bb0060]).

Adherence to methadone was measured using the medication possession ratio (MPR) and derived from administrative prescription data (PharmaNet). MPR is a validated ([@bb0170]) and well-established metric for adherence and has been used to measure long-term adherence in homeless mentally ill samples ([@bb0135], [@bb0140]). MPR indicates the ratio between the number of days of medication dispensed in a given time interval to the number of days in that interval. Drug costs, dispensing fees, and number of pharmacy transactions were determined separately (per person-year). PharmaCare billings and out-of-pocket patient expenses were also calculated.

Socio-demographic information was collected via questionnaires at recruitment. This also included information related to homelessness, such as age first homeless, lifetime duration of homelessness, and housing status (absolutely homeless or unstably housed). Twenty-nine chronic physical health conditions, diseases, and infections (e.g., HIV) were included in the VAH protocol. Mental disorders were categorized as being in the "less severe cluster" (includes: major depressive episode, post-traumatic stress disorder, and panic disorder) or "severe cluster" (includes: manic or hypomanic episode, mood disorder with psychotic features, and psychotic disorder). In addition to age of first alcohol and drug use, participants were asked if they had engaged in a range of substance use behaviors occurring in the previous month. Instrument details and information regarding methods of administration have been published ([@bb0165]).

2.3. Statistical analysis {#s0025}
-------------------------

Percentages were used to present results for each categorical variable. Descriptive statistics were presented for continuous variables.

The observation period used to assess adherence (MPR) consisted of the length of time (in days) between the date of first dispense (any time between January 1, 1996 and the baseline interview) and the date of the baseline interview. Continuous indication for MMT was assumed ([@bb0105]).

Independent sample *t*-tests (for categorical variables with two levels, such as gender and education) and one-way ANOVA (for categorical variables with more than two levels, such as ethnicity and lifetime duration of homelessness) were conducted to test for differences in MPR between levels of a variety of variables, including socio-demographic, homelessness, physical health, mental disorder, and substance use characteristics. All reported *p* values were two sided. The conventional *p* ≤ 0.05 was chosen to determine significance. Due to a small sample size, *p* ≤ 0.10 was also used to indicate a significant trend.

3. Results {#s0030}
==========

Baseline interviews for VAH were conducted with 497 participants, and 433 (87.1%) provided consent for researchers to access administrative data ([Table 1](#t0005){ref-type="table"}). PharmaNet records showed that methadone was dispensed to 78 participants (18.0%), of whom all but one had a diagnosis of drug dependence in MSP.Table 1Socio-demographic, physical health, mental disorder, and substance use characteristics of VAH participants at baseline who received methadone.Table 1VariableEntire sample (*n* = 497)Sample with administrative record (*n* = 433)\
Mean (SD)/n (%)Participants with drug dependence (*n* = 265)\
Mean (SD)/n (%)Methadone recipient (n = 78)\
Mean (SD)/n (%)Socio-demographicsWoman134 (27.2)112 (26.1)75 (28.6)30 (40.3)  Age at randomization\< 25 years36 (7.2)34 (7.9)17 (6.4)1 (1.3)25--44 years281 (56.6)242 (55.8)160 (60.4)52 (66.7)\> 44 years180 (36.2)157 (36.3)88 (33.2)25 (32.0)  EthnicityIndigenous77 (15.5)70 (16.2)56 (21.1)14 (17.9)White280 (56.3)235 (54.2)148 (55.9)47 (60.3)Other140 (28.2)128 (29.6)61 (23.0)17 (21.8)Incomplete high school280 (56.7)247 (57.4)166 (62.9)52 (66.7)Unemployed457 (92.3)398 (92.3)243 (92.0)76 (97.4)Income in past month (\<\$800)234 (47.7)198 (46.4)104 (39.7)31 (40.3)Single (never married)343 (69.6)293 (68.1)177 (67.6)44 (57.1)  HomelessnessAge of first homelessness (≥ 25 years)277 (56.4)239 (55.7)139 (52.9)40 (51.9)  Lifetime duration of homelessness≤ 12 months134 (27.3)122 (28.5)58 (22.1)10 (12.8)13--60 months203 (41.3)178 (41.6)115 (43.7)35 (44.9)\> 60 months154 (31.4)128 (29.9)90 (34.2)33 (42.3)Absolutely homeless388 (78.1)338 (78.1)207 (78.1)63 (80.8)  Physical healthHepatitis B25 (5.0)24 (5.5)21 (7.9)10 (12.8)Hepatitis C139 (28.0)125 (28.9)106 (40.0)55 (70.5)HIV/AIDS43 (8.7)39 (9.0)33 (12.5)15 (19.2)Any blood-borne infections (Hepatitis B, C, or HIV)157 (31.6)139 (32.1)114 (43.0)56 (71.8)Multiple (≥ 3) chronic health conditions344 (69.2)305 (70.4)200 (75.5)68 (87.2)  Mental disordersHospitalized for mental illness ≥ 2 times in the past 5 years253 (50.9)215 (49.7)131 (49.4)26 (33.3)Less severe cluster of mental disorders264 (53.1)235 (54.3)165 (62.3)58 (74.4)Severe cluster of mental disorders363 (73.0)311 (71.8)179 (67.5)46 (59.0)  Substance use behaviorsAge of first alcohol use (≤ 13 years)215 (45.6)185 (44.7)133 (51.4)48 (63.2)Age of first drug use (≤ 13 years)183 (40.0)159 (39.5)111 (43.0)33 (42.9)Use of injection drugs in past month88 (18.0)76 (17.8)65 (25.0)38 (50.0)Use of alcohol in past month225 (45.6)198 (45.9)130 (49.4)27 (35.1)Use of heroin in past month96 (19.4)89 (20.6)77 (29.3)45 (58.4)Weekly or daily heroin use in past month48 (9.7)46 (10.7)42 (16.0)28 (36.4)Use of benzodiazepine in past month41 (8.3)35 (8.1)30 (11.5)11 (14.3)Use of illicit methadone in past month21 (4.3)18 (4.2)16 (6.1)7 (9.1)Use of cocaine in past month83 (16.8)75 (17.4)58 (22.1)23 (29.9)Use of cocaine-crack base in past month160 (32.5)141 (32.8)121 (46.2)48 (62.3)Use of amphetamine in past month61 (12.4)51 (11.9)35 (13.3)13 (16.9)Use of cannabis in past month205 (45.3)186 (47.4)15 (6.4)38 (58.5)Use of ≥ 2 substances in past month (including alcohol)257 (52.0)230 (53.4)173 (65.8)62 (80.5)Daily alcohol use in past month26 (5.3)22 (5.1)16 (6.1)2 (2.6)Daily drug use (excluding alcohol) in past month126 (25.5)118 (27.4)87 (33.1)35 (45.5)Daily hard drug use (excluding alcohol and cannabis) in past month74 (15.0)67 (15.5)56 (21.3)27 (35.1)

Approximately 40% of participants who received methadone identified as women. The majority were between the ages of 25 and 44 years (66.7%), White (60.3%), had not completed high school (66.7%), and were single (never married) (57.1%). Additional socio-demographic details are presented in [Table 1](#t0005){ref-type="table"}.

Blood-borne infectious disease was prevalent among participants receiving methadone (71.8%), and multiple chronic physical health conditions were very common (87.2%). One third of the sample were hospitalized for mental illness two or more times in the past five years. Almost three-quarters of participants had a mental disorder from the "less severe cluster" (74.4%), whereas 59.0% had one from the "severe cluster".

In the month before baseline, half of participants had injected drugs, 80.5% used two or more substances (including alcohol), 2.6% used alcohol daily, 45.5% used drugs daily (excluding alcohol), and 35.1% used hard drugs daily (excluding alcohol and cannabis). Specific drugs used in the previous month, as well as the age of first drug and alcohol use are reported in [Table 1](#t0005){ref-type="table"}.

Mean MMT MPR was 0.47 (SD = 0.33), and while approximately a fifth of participants had an MMT MPR over 0.80, about a quarter had an MMT MPR ≤ 0.20 ([Table 2](#t0010){ref-type="table"}). Methadone was dispensed on a mean of 1140 days (SD = 1159 days). A mean of 2379 days (SD = 1543 days) or 6.5 years (SD = 4.2 years) elapsed between date of first dispense and VAH baseline. There were approximately 140 pharmacy transactions per person-year during the observation period, and the associated costs are presented in [Table 2](#t0010){ref-type="table"}.Table 2Methadone adherence, service, and cost during the study period (*n* = 78).Table 2Variablen (%)Number of days with methadoneMean (SD)1140 (1159)Median (IQR)787 (153, 1666)  Duration of MMT (between randomization and treatment initiation) in daysMean (SD)2379 (1543)Median (IQR)2211 (1006, 3611)  Duration of MMT (between randomization and treatment initiation) in yearsMean (SD)6.5 (4.2)Median (IQR)6.0 (2.8, 9.9)  Medication possession ratio (entire pre-period)Mean (SD)0.47 (0.33)  Medication possession ratio distribution (entire pre-period)≤ 0.2019 (24.4)0.21--0.4019 (24.4)0.41--0.6011 (14.1)0.61--0.813 (16.7)\> 0.8016 (20.4)Pharmacy transactions (\#), per person-year (entire pre-period)140.4Pharmacy transactions (\#), per person-year (past year)157.3PharmaCare costs (\$CAD), per person-year (past year)1714.9Patient costs (\$CAD), per person-year (past year)86.2Drug costs (\$CAD), per person-year (past year)325.2Pharmacy fee (\$CAD), per person-year (past year)1462.6

Comparisons of MMT MPR by participant characteristics are presented in [Table 3](#t0015){ref-type="table"}. A few significant differences were found. Of all socio-demographic variables, marital status was statistically significant; participants who were single and never married had a lower MPR (0.40 vs. 0.55, *p* = 0.036). Those with a mental disorder from the severe cluster had a significantly higher MMT MPR (0.54 vs. 0.37, *p* = 0.022). With regard to substance use variables, daily drug use (excluding alcohol) was associated with a significantly lower MMT MPR (0.39 vs. 0.54, *p* = 0.051). Weekly or daily heroin use was also associated with a lower MMT MPR, but this was marginally significant (0.38 vs. 0.52, *p* = 0.068), as was MMT MPR among those reporting polysubstance use compared to those who did not (0.44 vs. 0.61, *p* = 0.069).Table 3Bivariate comparisons of the methadone medication possession ratio by participant characteristics at baseline (*n* = 78).Table 3VariableMedication possession ratio (entire pre-period) (n = 78)\
Mean (SD)*p* value[a](#tf0005){ref-type="table-fn"}Socio-demographicsGender Woman0.45 (0.32)0.755 Man0.48 (0.34)Age at randomization ≤ 44 years0.45 (0.32)0.375 \> 44 years0.52 (0.34)Ethnicity Indigenous0.43 (0.30)0.805 White0.47 (0.34) Other0.51 (0.32)Education Incomplete high school0.44 (0.31)0.296 High school or higher0.52 (0.35)Marital Status Single (never married)0.40 (0.31)**0.036** Other0.55 (0.32)  HomelessnessAge of first homelessness \< 250.46 (0.32)0.626 ≥ 25 years0.49 (0.33)Lifetime duration of homelessness ≤ 12 months0.58 (0.28)0.370 13--60 months0.48 (0.32) \> 60 months0.42 (0.35)Housing status Absolutely homeless0.47 (0.34)0.751 Unstably housed0.44 (0.28)  Physical healthAny blood-borne infections (Hepatitis B, C, or HIV) Yes0.47 (0.32)0.994 No0.47 (0.35)Multiple (≥ 3) chronic health conditions Yes0.47 (0.33)0.928 No0.48 (0.34)  Mental disordersHospitalized for mental illness ≥ 2 times in the past 5 years Yes0.52 (0.32)0.303 No0.44 (0.33)Less severe cluster of mental disorders Yes0.46 (0.32)0.796 No0.49 (0.36)Severe cluster of mental disorders Yes0.54 (0.33)**0.022** No0.37 (0.30)  Substance use behaviorsUse of injection drugs in past month Yes0.50 (0.31)0.525 No0.45 (0.35)Use of alcohol in past month Yes0.46 (0.35)0.803 No0.48 (0.32)Use of heroin in past month Yes0.43 (0.31)0.217 No0.53 (0.34)Weekly or daily heroin use in past month Yes0.38 (0.31)*0.068* No0.52 (0.33)Use of cocaine in past month Yes0.49 (0.33)0.720 No0.46 (0.33)Use of cocaine-crack base in past month Yes0.45 (0.32)0.519 No0.50 (0.34)Use of cannabis in past month Yes0.40 (0.33)0.305 No0.49 (0.31)Use of ≥ 2 substances in past month (including alcohol) Yes0.44 (0.32)*0.069* No0.61 (0.32)Daily drug use (excluding alcohol) in past month Yes0.39 (0.32)**0.051** No0.54 (0.32)Daily hard drug use (excluding alcohol and cannabis) in past month Yes0.41 (0.29)0.249 No0.50 (0.34)[^1]

4. Discussion {#s0035}
=============

Relative to continuous adherence, the level of adherence observed in our sample was very low (mean MPR of 0.47) and may substantially undermine the opportunity to derive therapeutic value from this intervention ([@bb0005], [@bb0030], [@bb0070], [@bb0100], [@bb0180]). In contrast, using a similar adherence measure, [@bb0195] found that the percentage of "methadone use days" was 76.31% among MMT patients who had accessed community MMT clinics included in their analyses.

Poor adherence to MMT in our sample may be indicative of substance use concurrent with MMT. A previous study found opioid use during MMT to be significantly associated with lower MMT adherence ([@bb0130]). In our sample, reported substance use in the month preceding baseline was very common (e.g., heroin use, polysubstance use, and daily drug use). Further examination of substance use variables revealed that MMT MPR was significantly lower among methadone recipients who reported daily substance use in the month before baseline. Weekly or daily heroin use in the month before baseline was also associated with lower MMT adherence, albeit this finding was marginally significant. Substance use prior to treatment may also predict methadone adherence outcomes. For example, [@bb0145] found cocaine use, harmful alcohol use, and alcohol dependence to each be significantly associated with non-adherence to methadone when used before treatment. Our substance use-related findings may have important implications in the current context of increased opioid use-related overdose deaths ([@bb0025], [@bb0150]). In many jurisdictions, including BC, illicit drug use poses an unprecedented risk of overdose death, often attributed to illicit fentanyl ([@bb0025]). Our results suggest that despite having received MMT, homeless adults with mental illness were commonly using heroin and multiple illicit substances. Low prescribed MMT dosing may have also affected adherence ([@bb0155]) and illicit opioid use ([@bb0045]).

The prevalence of blood-borne infections, and chronic physical health conditions was very high in our sample. Nearly 20% of the sample was living with HIV/AIDS and 87.2% reported three or more chronic physical health conditions. This reflects the vulnerability of participants to chronic health issues in a context of long-term homelessness, serious mental illness, and drug dependence. Homelessness and unstable housing are associated with behaviors that increase risk of blood-borne infections ([@bb0010]). Homelessness and precarious housing also pose barriers to following treatment regimens, as competing priorities involving basic needs can interfere with adherence ([@bb0080]).

In addition to having competing priorities, however, homeless people may also face other barriers to access to health care, such as perceived discrimination, distrusting health practitioners, feeling dehumanized and unwelcomed ([@bb0175]), and perceiving office wait times to be long ([@bb0095]). Mental illness may also make it more difficult to access health care ([@bb0085]), but we found that participants who had a mental illness from the severe cluster of mental disorders had significantly higher MMT adherence. It could be that those living with schizophrenia, bipolar disorder, or a mood disorder with psychotic features are more closely monitored by health and social service providers while in MMT. More research is needed to elucidate this relationship.

Participants who reported being single and never married had significantly lower MMT MPR compared to those who did not. [@bb0185] found that having a good relationship with family was independently and significantly associated with greater MMT retention. Family members may provide support and encouragement for MMT recipients, and this can help inform MMT programs in terms of including family members in the treatment process ([@bb0185]).

With regard to cost, dispensing methadone represents a significant public investment. For example, while we found the cost of methadone itself to be \$325.20 per person-year in the year prior to the baseline interview, pharmacy fees entailed a 4.5 times greater cost at \$1462.60 per person-year during the same time-period. Future studies examining cost-effectiveness of MMT among homeless people experiencing mental illness are needed.

Addressing the housing and mental health needs of homeless and unstably housed MMT patients living with mental illness may be a necessary part of efforts to increase MMT adherence. [@bb0015] found higher MMT retention among those receiving supported housing, specifically Housing First. More research is needed to determine whether these findings extend to long-term MMT adherence. VAH demonstrated that 1) homeless adults with mental illness can be housed and supported ([@bb0160]) and that 2) scattered-site Housing First was associated with significantly greater antipsychotic medication adherence ([@bb0135]). The present study is preliminary in nature, and the first to quantify MMT adherence among homeless adults experiencing mental illness. Future research utilizing multivariable models to investigate variables associated with adherence in this population is needed. Alternative opioid maintenance treatments may be better options for some (e.g., injectable diacetylmorphine ([@bb0110])). It is also important to note that over 20% of our sample had an MMT MPR of over 0.80, considerably higher than the mean. Nevertheless, interventions to increase MMT adherence are needed for homeless and mentally ill methadone patients.

A few limitations should be noted. Prescription information detailing methadone dosage was unavailable. Data related to substance use prior to the month preceding baseline were also unavailable. Insufficient statistical power precluded us from conducting a multivariable analysis to estimate the association between selected variables and MMT MPR. Furthermore, the validity of self-reported data, especially substance use items, may have been compromised (underestimated) by social desirability bias or inaccurate recall. Participants were dispensed methadone within a universal health care system, limiting generalizability to dissimilar contexts. Additionally, we do not know the precise relationship between homelessness status and methadone adherence over the time-period observed for this study. Nevertheless, previous research on this sample has established that participants were profoundly marginalized from early ages, including significant adverse childhood experiences ([@bb0115], [@bb0120]), as well as family separation ([@bb0125]). Moreover, members of the sample had been homeless for roughly 10 years ([@bb0165]) and therefore were likely to have experienced substantial housing instability and marginalization throughout the period of time observed in the present study.

5. Conclusions {#s0040}
==============

This is the first study to investigate MMT adherence among homeless adults living with mental illness, and we found that on average, patients were using methadone less than half the time, despite low threshold access to MMT and publicly funded coverage. Adherence may be even lower among homeless adults experiencing mental illness in other settings without low threshold access to MMT. Chronic homelessness, infectious disease, and substance use were also very common. It remains extremely important to develop and implement interventions that increase MMT adherence among homeless mentally ill adults to decrease illicit opioid use and related harms. These efforts are needed immediately as opioid-related overdose deaths continue to rise, leading to premature mortality and increased demand on health and social resources. Drug use-related overdose deaths in BC have reached crisis levels, and in the month of November 2016, the mean number of people that died each day was over four ([@bb0090]). The number of deaths in 2016 was 922, a 79.7% increase compared to the preceding year ([@bb0025]). Housing and adequate supports may be a crucial part of the solution, not only to promote increased adherence to MMT, but also to alleviate physical and psychosocial harms associated with homelessness.
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[^1]: Bold indicates a significant difference at *p* ≤ 0.05 and italics indicate a significant trend (*p* \> 0.05 and *p* ≤ 0.10).
